SAN FRANCISCO, Dec. 26 - The proposed Genomica-Exelixis merger finally got its stock-exchange ratio. The ratio for converting shares of Genomica stock into shares of Exelixis stock will be 0.28306, the companies said on Wednesday .


To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.